CN102525970B - 一种抗痴呆药物口腔崩解片及其制备方法 - Google Patents
一种抗痴呆药物口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- CN102525970B CN102525970B CN201010624165.8A CN201010624165A CN102525970B CN 102525970 B CN102525970 B CN 102525970B CN 201010624165 A CN201010624165 A CN 201010624165A CN 102525970 B CN102525970 B CN 102525970B
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- cavity disintegration
- disintegration tablet
- huperzine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000214 mouth Anatomy 0.000 title claims abstract description 124
- 238000002360 preparation method Methods 0.000 title claims abstract description 112
- 229940125682 antidementia agent Drugs 0.000 title abstract description 61
- 239000002664 nootropic agent Substances 0.000 title abstract description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 101
- 239000003814 drug Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000004108 freeze drying Methods 0.000 claims abstract description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 120
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 111
- 239000008213 purified water Substances 0.000 claims description 83
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims description 79
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims description 79
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims description 79
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims description 79
- 239000004373 Pullulan Substances 0.000 claims description 72
- 229920001218 Pullulan Polymers 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 72
- 235000019423 pullulan Nutrition 0.000 claims description 72
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 66
- 229930195725 Mannitol Natural products 0.000 claims description 66
- 239000000594 mannitol Substances 0.000 claims description 66
- 235000010355 mannitol Nutrition 0.000 claims description 66
- 239000004471 Glycine Substances 0.000 claims description 60
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 53
- 239000000661 sodium alginate Substances 0.000 claims description 53
- 235000010413 sodium alginate Nutrition 0.000 claims description 53
- 229940005550 sodium alginate Drugs 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 51
- 238000002156 mixing Methods 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 22
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 21
- 229960004998 acesulfame potassium Drugs 0.000 claims description 21
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 21
- 239000000619 acesulfame-K Substances 0.000 claims description 21
- 238000003825 pressing Methods 0.000 claims description 19
- 235000015165 citric acid Nutrition 0.000 claims description 18
- 239000004376 Sucralose Substances 0.000 claims description 16
- 235000019408 sucralose Nutrition 0.000 claims description 16
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 16
- 108010011485 Aspartame Proteins 0.000 claims description 14
- 239000000605 aspartame Substances 0.000 claims description 14
- 235000010357 aspartame Nutrition 0.000 claims description 14
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 14
- 229960003438 aspartame Drugs 0.000 claims description 14
- 206010012289 Dementia Diseases 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 235000007119 Ananas comosus Nutrition 0.000 claims description 12
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 12
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 12
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 12
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 12
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007968 orange flavor Substances 0.000 claims description 6
- 239000011975 tartaric acid Substances 0.000 claims description 6
- 235000002906 tartaric acid Nutrition 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 229940109275 cyclamate Drugs 0.000 claims description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 4
- 230000012447 hatching Effects 0.000 claims description 4
- 238000001746 injection moulding Methods 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 102000006463 Talin Human genes 0.000 claims description 2
- 108010083809 Talin Proteins 0.000 claims description 2
- 244000290333 Vanilla fragrans Species 0.000 claims description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims 6
- 208000002173 dizziness Diseases 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 244000099147 Ananas comosus Species 0.000 claims 1
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 239000003795 chemical substances by application Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000010579 first pass effect Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 208000019505 Deglutition disease Diseases 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 231100000017 mucous membrane irritation Toxicity 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 95
- 208000024827 Alzheimer disease Diseases 0.000 description 16
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 16
- 229960003980 galantamine Drugs 0.000 description 14
- 229950010673 rivastigmine hydrogen tartrate Drugs 0.000 description 12
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 12
- 241000234671 Ananas Species 0.000 description 11
- 241000220223 Fragaria Species 0.000 description 11
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 10
- 229960003135 donepezil hydrochloride Drugs 0.000 description 10
- 239000000544 cholinesterase inhibitor Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 8
- 229960004640 memantine Drugs 0.000 description 8
- 210000002200 mouth mucosa Anatomy 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 7
- 229960004106 citric acid Drugs 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- -1 skeleton proppant Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 239000006191 orally-disintegrating tablet Substances 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 229960000967 memantine hydrochloride Drugs 0.000 description 3
- 229960004136 rivastigmine Drugs 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010036631 Presenile dementia Diseases 0.000 description 2
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
T16 | 3 | 3 | 3 | 4 | 3 | 3 | 3.2 |
T17 | 4 | 4 | 3 | 4 | 3 | 3 | 3.5 |
T18 | 3 | 4 | 4 | 3 | 4 | 3 | 3.5 |
T19 | 3 | 4 | 3 | 4 | 4 | 4 | 3.7 |
T20 | 4 | 3 | 3 | 3 | 3 | 3 | 3.2 |
T21 | 3 | 4 | 3 | 3 | 3 | 3 | 3.2 |
T22 | 3 | 4 | 4 | 4 | 4 | 3 | 3.7 |
组别 | 显效 | 有效 | 无效 | 总有效率(%) |
R1组 | 7 | 16 | 12 | 65.7 |
R2组 | 9 | 17 | 9 | 74.3 |
T1 | 13 | 18 | 4 | 88.6 |
T2 | 13 | 18 | 4 | 88.6 |
T3 | 12 | 19 | 4 | 88.6 |
T4 | 12 | 18 | 5 | 85.7 |
T5 | 12 | 18 | 5 | 85.7 |
T6 | 11 | 18 | 6 | 82.9 |
T7 | 13 | 18 | 4 | 88.6 |
T8 | 13 | 18 | 4 | 88.6 |
T9 | 12 | 18 | 5 | 85.7 |
T10 | 11 | 18 | 6 | 82.9 |
T11 | 11 | 19 | 5 | 85.7 |
T12 | 13 | 18 | 4 | 88.6 |
T13 | 12 | 18 | 5 | 85.7 |
T14 | 13 | 18 | 4 | 88.6 |
T15 | 11 | 18 | 6 | 82.9 |
T16 | 13 | 18 | 4 | 88.6 |
T17 | 11 | 19 | 5 | 85.7 |
T18 | 12 | 18 | 5 | 85.7 |
T19 | 11 | 18 | 6 | 82.9 |
T20 | 13 | 18 | 4 | 88.6 |
T21 | 12 | 19 | 4 | 88.6 |
T22 | 11 | 18 | 6 | 82.9 |
组别 | 显效 | 有效 | 无效 | 总有效率(%) |
R3组 | 6 | 16 | 13 | 62.9 |
R4组 | 7 | 18 | 10 | 71.4 |
T23 | 13 | 18 | 4 | 88.6 |
T24 | 13 | 18 | 4 | 88.6 |
T25 | 13 | 18 | 4 | 88.6 |
R5组 | 6 | 15 | 14 | 60.0 |
R6组 | 8 | 17 | 10 | 71.4 |
T26 | 12 | 18 | 5 | 85.7 |
T27 | 12 | 18 | 5 | 85.7 |
T28 | 11 | 19 | 5 | 85.7 |
R7组 | 7 | 16 | 12 | 65.7 |
R8组 | 8 | 17 | 10 | 71.4 |
T29 | 13 | 18 | 4 | 88.6 |
T30 | 13 | 18 | 4 | 88.6 |
T31 | 12 | 19 | 4 | 88.6 |
R9组 | 7 | 16 | 12 | 65.7 |
R10组 | 8 | 18 | 9 | 74.3 |
T32 | 13 | 18 | 4 | 88.6 |
T33 | 13 | 18 | 4 | 88.6 |
T34 | 12 | 19 | 4 | 88.6 |
T35 | 13 | 18 | 4 | 88.6 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010624165.8A CN102525970B (zh) | 2010-12-31 | 2010-12-31 | 一种抗痴呆药物口腔崩解片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010624165.8A CN102525970B (zh) | 2010-12-31 | 2010-12-31 | 一种抗痴呆药物口腔崩解片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102525970A CN102525970A (zh) | 2012-07-04 |
CN102525970B true CN102525970B (zh) | 2015-11-25 |
Family
ID=46334804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010624165.8A Active CN102525970B (zh) | 2010-12-31 | 2010-12-31 | 一种抗痴呆药物口腔崩解片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102525970B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY191260A (en) * | 2016-12-23 | 2022-06-12 | Oxford BioDynamics PLC | Typing method |
CN112494450A (zh) * | 2020-12-12 | 2021-03-16 | 海南海神同洲制药有限公司 | 化学药专用口腔崩解片包覆结构及其制备方法 |
CN112641741A (zh) * | 2020-12-29 | 2021-04-13 | 卓和药业集团有限公司 | 一种含有重酒石酸卡巴拉汀的口崩片及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689649A (zh) * | 2004-04-30 | 2005-11-02 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
CN1709229A (zh) * | 2005-06-10 | 2005-12-21 | 北京阜康仁生物制药科技有限公司 | 盐酸美金刚口腔崩解片及其制备方法 |
CN1915215A (zh) * | 2005-08-17 | 2007-02-21 | 量子高科(北京)研究院有限公司 | 一种口腔崩解制剂 |
CN101007002A (zh) * | 2006-01-25 | 2007-08-01 | 北京奇源益德药物研究所 | 石杉碱甲小丸制剂及其制备方法 |
CN101756917A (zh) * | 2008-10-24 | 2010-06-30 | 北京科信必成医药科技发展有限公司 | 盐酸多奈哌齐口腔崩解片及其制备方法 |
-
2010
- 2010-12-31 CN CN201010624165.8A patent/CN102525970B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689649A (zh) * | 2004-04-30 | 2005-11-02 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
CN1709229A (zh) * | 2005-06-10 | 2005-12-21 | 北京阜康仁生物制药科技有限公司 | 盐酸美金刚口腔崩解片及其制备方法 |
CN1915215A (zh) * | 2005-08-17 | 2007-02-21 | 量子高科(北京)研究院有限公司 | 一种口腔崩解制剂 |
CN101007002A (zh) * | 2006-01-25 | 2007-08-01 | 北京奇源益德药物研究所 | 石杉碱甲小丸制剂及其制备方法 |
CN101756917A (zh) * | 2008-10-24 | 2010-06-30 | 北京科信必成医药科技发展有限公司 | 盐酸多奈哌齐口腔崩解片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
盐酸多奈哌齐口崩片的处方优选及稳定性研究;侯林中等;《中国药房》;20061231;第17卷(第17期);第1301-1303页 * |
石杉碱甲口腔崩解片的制备及溶出度考察;袁易等;《药学服务与研究》;20060831;第6卷(第4期);第274-276页 * |
Also Published As
Publication number | Publication date |
---|---|
CN102525970A (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100215740A1 (en) | Taste-masked orally disintegrating tablets of memantine hydrochloride | |
CN100540012C (zh) | 一种柴胡提取物、其制备方法及其应用 | |
WO2000078292A1 (fr) | Preparations solides a desintegration rapide | |
CN101756917A (zh) | 盐酸多奈哌齐口腔崩解片及其制备方法 | |
CN102525970B (zh) | 一种抗痴呆药物口腔崩解片及其制备方法 | |
CN102552191B (zh) | 一种5-ht受体激动剂口腔崩解片及其制备方法 | |
CN103120652B (zh) | 间苯三酚口腔崩解片及其制备方法 | |
CN102631329A (zh) | 一种帕罗西汀的口服崩解片及制备工艺 | |
CN104873458A (zh) | 一种沃替西汀冻干口腔崩解片及其制备方法 | |
WO2006109737A1 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
CN104415097A (zh) | 荷叶或莲子心中总生物碱的舌下给药制剂及用途 | |
CN102525972B (zh) | 一种钙离子拮抗剂口腔崩解片及其制备方法 | |
CN102579376B (zh) | 一种非甾体抗炎药口腔崩解片及其制备方法 | |
CN101401796A (zh) | 普拉克索口腔崩解片及其制备方法 | |
CN101822646B (zh) | 一种盐酸非索非那定口腔崩解片及其制备方法 | |
CN102552192A (zh) | 一种镇静催眠药口腔崩解片及其制备方法 | |
CN102309460B (zh) | 溴吡斯的明掩味口腔崩解片及其制备方法 | |
JP2008094751A (ja) | プランルカスト水和物含有医薬組成物 | |
CN102451167A (zh) | 一种h1受体拮抗剂口腔崩解片及其制备方法 | |
CN102309461B (zh) | 溴吡斯的明掩味分散片及其制备方法 | |
CN102451169A (zh) | 氯雷他定冻干片及其制备方法 | |
CN1857342A (zh) | 沙棘制剂及其制备方法 | |
JPH11116465A (ja) | 迅速溶解性製剤およびその製造法 | |
CN102525971A (zh) | 一种促胃肠动力药口腔崩解片及其制备方法 | |
CN102451170B (zh) | 盐酸格拉司琼冻干片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 102200 Changping District Road, Beijing, No. 8, No. 11 building Applicant after: QUANTUM HI-TECH (BEIJING) Research Institute Address before: 065201 Yingbin Road, Yanjiao economic and Technological Development Zone, Langfang, Hebei Applicant before: QUANTUM HI-TECH (BEIJING) Research Institute |
|
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120704 Assignee: Shanxi Liangzi High-tech Drug Co.,Ltd. Assignor: QUANTUM HI-TECH (BEIJING) Research Institute Contract record no.: 2016990000053 Denomination of invention: Anti-dementia medicinal orally disintegrating tablet and preparation method thereof Granted publication date: 20151125 License type: Exclusive License Record date: 20160226 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191018 Address after: Room 503, building 11, yard 8, Heying Road, east industrial base, science and Technology Park, Changping District, Beijing 102200 (Changping demonstration area) Patentee after: BEIJING QUANTUM HI-TECH PHARMACY TECHNOLOGY Co.,Ltd. Address before: 102200, No. 11, building 8, Ho Ying Road, Beijing, Changping District Patentee before: QUANTUM HI-TECH (BEIJING) Research Institute |
|
TR01 | Transfer of patent right |